National Centre for Asbestos Related Diseases

Exploiting checkpoint blockade immunotherapy to improve treatment of malignant mesothelioma

Further Information

  • All current grants
  • All previous grants

Immune checkpoint blockade (ICPB) has demonstrated effective therapy in melanoma and is now being applied to other cancers, including malignant mesothelioma (MM).

Dust Diseases Board of NSW

ICPB therapies work by using antibodies to block molecules that negatively regulate T cell activation, thus promoting and prolonging anti-tumour immunity. Current ICPB therapies are mostly focused on two key checkpoint molecules; CTLA-4 and PD-1. However, at least 22 different checkpoint molecules have been identified and the best combinations for each cancer setting have yet to be fully elucidated.

Using our well established preclinical mesothelioma models, this study aims to characterise the expression profile of checkpoint molecules on immune cells present within mesothelioma tumours to identify the best combination of checkpoint blockade antibodies that generate effective therapy against mesothelioma.

These findings will be fundamental to inform the rational design of future clinical trials that utilise ICPB for the treatment of MM.

Back to top


National Centre for Asbestos Related Diseases

This Page

Last updated:
Tuesday, 1 December, 2015 1:40 PM